January 15, 2001
AMERIPATH RESTRUCTURES SALES AND MARKETING ORGANIZATION

Riviera Beach, FL, January 15, 2001 - AmeriPath Inc, (NASDAQ: PATH), the nation's largest company focused on providing anatomic pathology, cancer diagnostic and related healthcare information services, announced today that it has divided its sales and marketing organizations into two separate divisions.

After the completion of market research, including customer focus groups and the demographic distribution of patients and referring physicians, along with closely examining the current business model, two distinct field sales organizations have been created to provide dedicated service and support to referring physicians along specialty lines.  Both organizations will be under the direction of Bruce Walton, Vice President of Sales, Marketing and Contracting.

Dermpath Diagnostics, which will be led by Annette L. Bell, Vice President and General Manager, will focus on servicing and growing the national skin pathology market comprised of dermatologists, plastic surgeons, family practitioners, otolaryngologists, and podiatrists. This division, which represents AmeriPath's 67 board-certified dermatopathologists, will expand its sales and marketing initiative throughout the U.S. market.

The existing AmeriPath field sales organization, led by Ed Dooling, Vice President and General Manager, has the responsibility for servicing and growing the outpatient anatomic pathology market with urologists, gastroenterologists, gynecologists, surgery centers, oncologists and any specialist requiring esoteric laboratory testing, which is provided through our Center for Advanced Diagnostics.

AmeriPath's Contracting Division will support both organizations in managed care contracting efforts in the field.

AmeriPath's Chairman and Chief Executive Officer, James C. New, commented, "These newly developed sales and marketing divisions are comprised of over 40 sales professionals who are dedicated to responding to the specific needs of our referring physicians and their patients.  This strategic positioning enables AmeriPath to better serve our customers and meet or exceed our same store growth initiatives for 2001."

AmeriPath, Inc. is the nation's largest company focused on providing anatomic pathology, cancer diagnostic and related healthcare information services to physicians, hospitals, national clinical laboratories and managed care organizations.  The Company's 426 physicians provide medical services through 42 outpatient pathology laboratories, 224 hospital inpatient laboratories, and 64 outpatient surgery centers in 21 states. 

....................................................................................................................

The statements of James C. New and other statements contained in this press release are "forward-looking statements" which are based on current beliefs and expectations. Past performance is not necessarily indicative of future results. In addition, forward-looking statements - which are identified by words such as "may", "should", "believe," "expect," "anticipate" and similar expressions -- are subject to a number of risks and uncertainties which could cause actual results to differ materially from historical results or those expected or anticipated. These include risks and uncertainties relating to satisfaction of closing conditions, demand for pathology services, pricing, federal and state regulation (and compliance), reimbursement rates, government and third party payments, the ability to attract, motivate, and retain pathologists, dependence upon pathologists and contracts, the development and expansion of managed care and national clinical lab contracts, completion and integration of acquisitions and affiliations (and achievement of planned or expected synergies), competitive factors and technology. Further information regarding risks, uncertainties and other factors that could affect the Company's financial results, or could cause actual results to differ materially from those expected or anticipated, are included in the Company's Form 10-K for the year ended December 31, 1999 and subsequent filings with the SEC.